Company presentation. 7 th European Life Science CEO Forum Zurich, 4-5 March Paolo Bassanini Business Development & IR

Size: px
Start display at page:

Download "Company presentation. 7 th European Life Science CEO Forum Zurich, 4-5 March 2014. Paolo Bassanini Business Development & IR"

Transcription

1 Company presentation 7 th European Life Science CEO Forum Zurich, 4-5 March 2014 Paolo Bassanini Business Development & IR

2 Forward-looking statements The presentation contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This presentation is not an offer of securities for sale in any country or jurisdiction, including the United States. Securities may not be sold to the public in the United States, in Australia, in Canada, in Japan, or in other relevant jurisdictions without complying with local registration requirements and other legal restrictions. Declaration by the official Corporate Financial Reporting Manager: The undersigned herewith attests, pursuant to Article 154-bis, paragraph 2 of the Italian Consolidated Law on Finance (Legislative Decree 58/1998), that the accounting disclosure contained in this presentation matches documentary evidence, corporate books, and accounting records. Andrea Quaglino, Director administration, finance and control 2

3 MolMed: at a glance Listed on the Milan Stock Exchange: Mk Cap (Feb 28 th ) ~ 155 million (+60% YoY) Company Focus: oncology and genetic orphan diseases 118 employees, 2/3 staff scientists Company core competencies: Recombinant proteins NGR-hTNF: tumor vascular targeting agent proof of efficacy in randomized Phase II trials, long-term safety data established, pivotal Phase III results in 1H 2014 Cell and gene therapies TK: cell therapy product expected filing for Conditional Approval in EU in 1Q2014 Projects with Third Parties: development and production of gene & cell therapies for rare genetic diseases constantly growing revenues (+11,9% 30 Sept. 2013) 3

4 Shares information As of February 20 th, 2014: Number of shares (fully diluted): Free Float: 48.37% Daily traded volume (average 3 months): ~ 2,300,000 shares Shareholder s structure: Fininvest 24.90% Science Park Raf 8,34% Free float Others (<2%) 48.37% Airain 6.65% Delfin 4.06% H-Invest 3.62% H-Equity 4.06% Strategic investors 4

5 Key financials ( thousand) (first 9 months) 2012 (first 9 months) Operating revenues 5,059 3,418 2, Revenues from activities for third parties 4,593 2,767 2, Other income Operating costs (27,441) (26,098) (20,424) (17.894) (20.076) Result for the period (22,001) (21,569) (17,582) (14.654) (16.733) ( thousand) Dec 31 st 2012 Dec 31 st 2011 Dec 31 st 2010 Sep. 30 th 2013 Sep. 30 th 2012 Net financial position 17,526 38,667 60,

6 MolMed business model: innovation and risk mitigation Two innovative platforms with different business strategies Recombinant proteins Cell and gene therapy NGR-hTNF TK Projects with 3 rd Parties Tumour vascular targeting Potential blockbuster Patient-specific product for high-risk leukaemia Patient-specific cell & gene therapies Partnering Own commercialisation vs partnering opportunities R&D & production for third parties / partnerships 6

7 Advanced clinical development TK Phase II Phase III RANDOM. Placebo High-risk Leukemia * Comments Seeking Conditional Approval in EU Competition Low NGR-hTNF RANDOM. Placebo Pleural mesothelioma* 2 nd line Results in 1H14 None RANDOM. Placebo Pleural mesothelioma* 1 st line maintenance Completing enrolment in 1H14 None RANDOM. Ovarian cancer 2 nd line Results in 1H14 Medium RANDOM. Soft-tissue sarcomas 1 st line Results in 1H14 Low RANDOM. Non-small cell lung cancer 1 st line Completed Low (squamous) *Orphan Drug Designation Liver cancer * 2 nd line Small-cell lung cancer 2 nd line Colorectal cancer 2 nd line Completed Completed Completed Low High High Study completed Recruitment completed, follow-up ongoing Recruitment ongoing 7

8 NGR-hTNF: an anti-tumor fusion protein NGR peptide selectively binding to CD13 on tumor neo-vasculature htnf (human Tumor Necrosis Factor) powerful anti-tumor agent binding to the TNF-Receptor Molecule with unique biological properties Boosting activity of chemotherapy administered in combination Direct anti-tumour activity at very low doses (0.8 µg/sqm) with no toxic side effects 8

9 NGR-hTNF: selective vascular targeting agent Human colon carcinoma Normal human colon CD31 (green) + NGR-Qd (red) CD31 (green) + NGR-Qd (red) Whole mount analysis of tissues obtained from the same patient (N=3) NGR binds to tumour vessels of CRC and not to those of normal intestine 9

10 NGR-hTNF: very low toxicity profile More than 1000 patients treated so far: No grade 3-4 drug-related toxicity No cumulative toxicity No treatment discontinuations due to toxicity No worsening of chemo-associated toxicities No pulmonary hemorrhage or bleeding events Suitable for long-term maintenance treatment 10

11 Median change from baseline (%) Survival probability NSCLC: final data show statistically significant survival improvement in squamous subset 1 Phase II Randomized + Cisplatin and Gemcitabine 1 st line Decrease in tumour size over treatment Overall survival (n=35) 0 2 nd 4 th 6 th (cycle) Time (months) Note: 1 Predefined per protocol After a 2.5-year follow-up time, there is a more than 50% relative reduction in the risk of death 11

12 Soft Tissue Sarcomas: data show statistically significant survival benefit Phase II Randomized + Doxorubicin (60mg/sqm) 2 nd line Overall survival (n=69) Low-dose NGR-hTNF plus doxorubicin induces a statistically significant 100% increase in median survival (p=0.03) 12

13 Mesothelioma: treatment intensification leads to longer patient benefit Phase II Single arm Monotherapy 2 nd line Doubled median survival duration versus historical controls OS rates by schedule NGR-hTNF Ph II (n=57) Placebo vs Monochemoth. Ph III (n=660)* Median PFS (months) vs 1.4 Median OS (months) vs 7.1 *Krug LM et al. EMCC year follow-up results strongly confirm the benefit of dose intensification: survival rate increased 4-5 fold 13

14 Mesothelioma: pivotal Phase III trial as 2 nd line therapy (NGR015) Patients pre-treated with pemetrexed-based regimen (n=390) N=195 Randomization 1:1 N=195 NGR-hTNF (0.8 µg/sqm q1w) + Best Investigator s Choice Placebo + Best Investigator s Choice Design: double-blind, placebo-controlled, with a 1:1 randomization ratio Primary endpoint: overall survival (N=390; 80% power; 0.05 alpha level; HR=0.72) Status: enrolment completed (400 pts. in EU, US, Canada and Egypt) Primary efficacy analysis: expected during first half 2014 Competition: no approved drug in second line 14

15 NO THERAPY ALIMTA Mesothelioma: a new therapeutic plan Present therapeutic option 1. Only approved 1 st line treatment is the administration of pemetrexed (Alimta, Eli Lilly) in combination with cisplatin: average treatment duration months because of maximal cumulated toxicity 2. 70% of patients relapse within 1.5 months (median) from the completion of the first line treatment 1. Currently there is no approved drug for second line treatment of pleural mesothelioma MolMed s therapeutic option NGR-hTNF currently in Phase II as maintenance treatment: administered immediately after the pemetrexed to extend the time before relapse 100% of patients exiting 1 st line therapy are eligible NGR-hTNF currently in Phase III as 2 nd line treatment: administered after relapse to extend patients overall survival 15

16 NGR-hTNF incidence of indications: well positioned to become a potential blockbuster Indications Clinical Phase Incidence (EU27, USA, CA) Incidence (CN, JP) Total Primary indications Pleural Mesothelioma Pleural Mesothelioma NSCLC Second line ) First line Maintenance III 5'800 2' II 8'300 3' ' '000 II Squamous histology 140' ' '000 Soft tissue sarcomas II 29'200 30' Other relevant indications Ovarian cancer Liver cancer 77' '000 II Platinum resistant 36'000 60'000 96' ' '000 II Sorafenib resistant 70' ' '000 SCLC 152' ' Total 500'000 > 500'000 >

17 NGR-hTNF: competitive scenario key indications Malignant Pleural Mesothelioma (2nd line) No Approved Drug NGR-hTNF only candidate in Phase III clinical development Malignant Pleural Mesothelioma (1st line maintenance) No Approved Drug 1 candidate drug in Phase II clinical development (FAK inhibitor, Small Molecule) NGR-hTNF in Phase II clinical development Squamous NSCLC (1st line) No Approved Drug 2 drug candidates in Phase III clinical development (EFGR Antagonist, mab and mab) NGR-hTNF in Phase II clinical development Soft Tissue Sarcomas (2nd line) 1 approved drug (Votrient - PK Inhibitor, Small Molecule), high liver toxicity 1 drug approved only in EU (Yondelis - DNA Intercalator, Small Molecule) 1 candidate in Phase II clinical development (Cox-2 Inhibitor/ G Protein Coupled Receptor Mas Agonist, Peptide NGR-hTNF in Phase II clinical development 17

18 freedom-to-operate Exclusivity NGR-hTNF: Intellectual Property protection worldwide Use for the treatment of mesothelioma is covered by patent until 2029 NGR-TNF conjugate patent: granted in US, EU, Japan, South Korea and China, valid until 2021, extendable with Supplementary Protection Certificate until 2026 Exclusivity and freedom to operate through proprietary and in-licensed patents Patent claims Family Coverage (underlined = granted) Exp. Use in mesothelioma WO AU, CA, US, JP, EP, CN, IL, IN, KR, NZ, RU, ZA 2029 NGR-TNF conjugate = composition of matter Use in combination with IFNg Use at low dosage in combination with chemotherapy NGR peptide WO AU, CA, US, JP, EP (AL, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LT, LU, LV, MC, MK, NL, PT, RO, SE, SI, SK, SL, TR) CN, CZ, BG, EA, HK, HU, IL, IN, KR, SG, BR, MX, NO, PL, UA, UZ, ZA 2021 (with SPC 2026) WO AU, CA, CN, US, JP, EP (DE, ES, FR, GB, IT) 2023 WO US , US WO WO AU, CA, US, JP, EP, CN, EA, HK, IL, IN, NO, KR, ZA CA, EP (DE, GB, IT, FR, CH), US CA, EP (DE; GB; IT, FR, CH), US

19 NGR-hTNF: gearing up for marketing authorization in mesothelioma as first indication Enrolment completed in pivotal Phase III (400 patients), results expected during first half 2014 Results of two randomised Phase II trials in key indications (OC and STS) expected during first half 2014 High unmet medical need and low competition scenario: no drugs registered for second-line treatment or in Phase III development Orphan Drug designation + patent protection up to 2029 Development of commercial-scale manufacturing ongoing for liquid and lyophilized formulations: Low COGS: obtained by fermentation in E.coli (one single gene construct) Strong margin, also in case of price pressure or intense competition Business strategy: out-licensing / partnering 19

20 Thanks for your attention

MolMed S.p.A. Investor presentation

MolMed S.p.A. Investor presentation an integrated strategy to cure cancer MolMed S.p.A. Investor presentation BIO CEO & Investor Conference, New York (USA) 9 February 2010 Claudio Bordignon Chairman & CEO Forward-looking statements This

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

OHIM SEARCH TOOLS: TMVIEW, DSVIEW AND TMCLASS. Making trade mark and design information readily available for users

OHIM SEARCH TOOLS: TMVIEW, DSVIEW AND TMCLASS. Making trade mark and design information readily available for users OHIM SEARCH TOOLS: TMVIEW, DSVIEW AND TMCLASS Making trade mark and design information readily available for users Mariano Riccheri Moscow, 24 September 2015 INTERNATIONAL COOPERATION AREA European Cooperation:

More information

European Research Council

European Research Council ERC Starting Grant Outcome: Indicative statistics Reproduction is authorised provided the source ERC is acknowledged ERCEA/JH. ERC Starting Grant: call Submitted and selected proposals by domain Submitted

More information

Annex A to the MPEG Audio Patent License Agreement Essential Philips, France Telecom and IRT Patents relevant to DVD-Video Player - MPEG Audio

Annex A to the MPEG Audio Patent License Agreement Essential Philips, France Telecom and IRT Patents relevant to DVD-Video Player - MPEG Audio Annex A to the MPEG Audio Patent License Agreement Essential Philips, France Telecom and IRT Patents relevant to DVD-Video Player - MPEG Audio PUBLICATION AR N 015678 - P970100444 05-Feb-97 17-Oct-05 AR006969

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

2015 Half Year Results Conference Call Presentation. 26 August 2015

2015 Half Year Results Conference Call Presentation. 26 August 2015 2015 Half Year Results Conference Call Presentation 26 August 2015 1 Today s Call Participants Dr Patrik De Haes - CEO Dominique Vanfleteren CFO 2 Agenda for the Call 2015 Highlights US update : objectives

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Axioma Risk Monitor Global Developed Markets 29 June 2016

Axioma Risk Monitor Global Developed Markets 29 June 2016 Axioma Risk Monitor Global Developed Markets 29 June 2016 1. Global volatility hotspots 2. Global correlation hotspots www.axioma.com Greater than 1% rise over last week Greater than 1% fall over last

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Title (fr) SOURCE IONIQUE INTERNE DOUBLE POUR PRODUCTION DE FAISCEAU DE PARTICULES AVEC UN CYCLOTRON

Title (fr) SOURCE IONIQUE INTERNE DOUBLE POUR PRODUCTION DE FAISCEAU DE PARTICULES AVEC UN CYCLOTRON Title (en) A TWIN INTERNAL ION SOURCE FOR PARTICLE BEAM PRODUCTION WITH A CYCLOTRON Title (de) DOPPELTE INTERNE IONENQUELLE FÜR PARTIKELSTRAHLHERSTELLUNG MIT EINEM ZYKLOTRON Title (fr) SOURCE IONIQUE INTERNE

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1 COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize

More information

Clinical Trials for Patients with

Clinical Trials for Patients with Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,

More information

Corporate Presentation June 2, 2015

Corporate Presentation June 2, 2015 Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

BNC105 PHASE II RENAL CANCER TRIAL RESULTS

BNC105 PHASE II RENAL CANCER TRIAL RESULTS ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Mesothelioma Applied Research Foundation www.curemeso.org

Mesothelioma Applied Research Foundation www.curemeso.org Mesothelioma Applied Research Foundation www.curemeso.org Board of Directors Michael Becich PhD Gen. Steven Blum Lee Krug MD David Ettinger MD Axel Ranier Richard Mosca Erica Iacono Terry Lynch Hanne Minz

More information

Statutory financial statements at 31 December 2011

Statutory financial statements at 31 December 2011 Statutory financial statements at Approved by the Shareholders Meeting of 23 April 2012 English translation for convenience MolMed S.p.A. is a biotechnology company focused on research, development and

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Retirement Readiness. OECD/IOPS GLOBAL FORUM ON PRIVATE PENSIONS - Sydney Nov 2-3

Retirement Readiness. OECD/IOPS GLOBAL FORUM ON PRIVATE PENSIONS - Sydney Nov 2-3 Retirement Readiness OECD/IOPS GLOBAL FORUM ON PRIVATE PENSIONS - Sydney Nov 2-3 Brigitte Miksa, Head of International Pensions, Allianz Global Investors AG November 2010 New funded pension schemes shape

More information

HU CZ FI PL SI PT IT ES NO NL FR DK SE IE GB AT DE CH LU 0 10 20 30 40 Foreigners' share Source: Eurostat More trust 3 4 5 6 7 PL HU CZ SI PT GR ES DK FI SE

More information

Endpoint Selection in Phase II Oncology trials

Endpoint Selection in Phase II Oncology trials Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles

More information

Navigating GIST. The Life Raft Group June 12, 2008

Navigating GIST. The Life Raft Group June 12, 2008 Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting

More information

Malignant Mesothelioma - Pipeline Review, H2 2014

Malignant Mesothelioma - Pipeline Review, H2 2014 Brochure More information from http://www.researchandmarkets.com/reports/2888197/ Malignant Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Mesothelioma - Pipeline Review, H2 2014 Summary

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

TEPZZ 87_546A T EP 2 871 546 A2 (19) (11) EP 2 871 546 A2 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: G05B 19/05 (2006.01)

TEPZZ 87_546A T EP 2 871 546 A2 (19) (11) EP 2 871 546 A2 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: G05B 19/05 (2006.01) (19) TEPZZ 87_46A T (11) EP 2 871 46 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 13.0.1 Bulletin 1/ (1) Int Cl.: G0B 19/0 (06.01) (21) Application number: 14188238.1 (22) Date of filing:

More information

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of

More information

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES

NATIONAL CANCER DRUG FUND PRIORITISATION SCORES NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Milk Market Situation. Brussels, 27 August 2015

Milk Market Situation. Brussels, 27 August 2015 Milk Market Situation Brussels, 27 August EU Productions EU Productions (Jan-Jun compared to Jan-Jun 214) +,8% + 1,2% + 3,2% +,2% +,7% - 2,% - 3,1% -,1% - 11,1%!!! Data from some Member States are confidential

More information

FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015. Pre- and Post- Event Questionnaires

FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015. Pre- and Post- Event Questionnaires FH Studies Collaboration Lecturers at the European Society of Atherosclerosis Congress 2015 Pre- and Post- Event Questionnaires The information on these slides is intended for educational purposes only.

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

BIS CEMLA Roundtable on Fiscal Policy, public debt management and government bond markets: issues for central banks

BIS CEMLA Roundtable on Fiscal Policy, public debt management and government bond markets: issues for central banks BIS CEMLA Roundtable on Fiscal Policy, public debt management and government bond markets: issues for central banks Is monetary policy constrained by fiscal policy? by Carlos Montoro 26-27 November 212

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D.

FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS. Jonathan Pachter, Ph.D. FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010 The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche Erlotinib for the treatment of non-small cell lung cancer Report from the Decision Support Unit in response to additional data submitted by Roche 10 th January 2008 Part 1: A Sutton. Critique of the network

More information

MM, EFES EN. Marc Mathieu

MM, EFES EN. Marc Mathieu MM, EFES EN Marc Mathieu La Tribune Hewitt EUROPEAN EMPLOYEE OWNERSHIP ACROSS THE CRISIS Numbers 2006/2007/2008/2009 2009 2008 2007 2006 Employee owners 9.3 million 9.0 million 8.4 million Employees' share

More information

Cancer patients waiting for potentially live-saving treatments in UK

Cancer patients waiting for potentially live-saving treatments in UK Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

Second Quarter Report

Second Quarter Report Second Quarter Report Oncolytics Biotech Inc. TSX: ONC NASDAQ: ONCY Oncolytics Message to Shareholders In an effort to maximize the future commercial potential of REOLYSIN, we continue to build upon and

More information

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Investor & Analyst Presentation Eigenkapitalforum Frankfurt November 24-26th, 2014. Dr. Cornelius Patt, CEO Andreas Grandinger, CFO

Investor & Analyst Presentation Eigenkapitalforum Frankfurt November 24-26th, 2014. Dr. Cornelius Patt, CEO Andreas Grandinger, CFO Investor & Analyst Presentation Eigenkapitalforum Frankfurt November 24-26th, 2014 Dr. Cornelius Patt, CEO Andreas Grandinger, CFO Safe Harbor Statement This document includes supplemental financial measures

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

TEPZZ 9 Z5A_T EP 2 922 305 A1 (19) (11) EP 2 922 305 A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art.

TEPZZ 9 Z5A_T EP 2 922 305 A1 (19) (11) EP 2 922 305 A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art. (19) TEPZZ 9 ZA_T (11) EP 2 922 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 13(4) EPC (43) Date of publication: 23.09.1 Bulletin 1/39 (21) Application number: 1386446.2 (22) Date

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

European Research Council

European Research Council ERC Advanced Grants 2011 Outcome: Indicative Statistics Reproduction is authorised provided that the source ERC is acknowledged NB: In these graphs grantee refers to a candidate selected for ERC funding

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. July 22, 2015 CheckMate -025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early (PRINCETON, NJ, July 20, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

Czech Universities and the Environment for Innovation. Rudolf Hanka

Czech Universities and the Environment for Innovation. Rudolf Hanka Czech Universities and the Environment for Innovation Rudolf Hanka Czech Republic a cauldron of Central Europe? Geographical position Major motorways High speed backbone network Czech internet network

More information

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer

Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure 11 th Annual Needham Healthcare Conference April 3, 2012 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

How valuable is a cancer therapy? It depends on who you ask.

How valuable is a cancer therapy? It depends on who you ask. How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr

More information

The long term policy view: Shifting Wealth, Income Inequalities and Demography - The Ageing Report

The long term policy view: Shifting Wealth, Income Inequalities and Demography - The Ageing Report The long term policy view: Shifting Wealth, Income Inequalities and Demography - The Ageing Report Per Eckefeldt European Commission Directorate General for Economic and Financial Affairs XXV Villa Mondragone

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Gene Silencing Oligos (GSOs) Third Generation Antisense

Gene Silencing Oligos (GSOs) Third Generation Antisense Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information